Aras, E., Bayraktar, A., & Kilickap, S. (2020). Risk assessment of febrile neutropenia and evaluation of G-CSF use in patients with cancer: a real-life study. Supportive Care in Cancer,28, 691-699.http://doi.org/10.1007/s00520-019-04879-x
Dale, D. C., Crawford, J., Klippel, Z., Reiner, M., Osslund, T., Fan, E., Morrow, P. K., & Lyman, G. H. (2018). A systematic literature review of efficacy effectiveness and safety of filgrastim. Support Care in Cancer, 26(1), 7-20. http://doi.org/10.1007/s00520-017-3854-x
Lambrix, A. A., Jodele, S., Lane, A., Grimley, M. S., Davies, S. M., & Teusink-Cross, A. (2018). Impact of delayed (day +7) filgrastim administration on time to engraftment and incidence of infection. Biology of Blood and MarrowTransplatation, 24(3), S333. http://doi.org/10.1016/j.bbmt.2017.12.278
Othman, T. B., Ghedira, H., Abdejlil, N. B., Lakhal, A., Torjemane, L., & Ladeb, S. (2018). Filgrastim following HLA-identical allogeneic bone marrowtransplantation: Long-term outcomes of a randomized trial. Biology of Blood and Marrow Transplatation, 24(12), 2459-2465. http://doi.org/10.1016/j.bbmt.2018.07.024